Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by blackascanbeon Feb 17, 2012 12:42pm
325 Views
Post# 19550096

Thanks Prested...Jesus was also abused

Thanks Prested...Jesus was also abused

Abuse is usually delivered by angry, confused people. In response to your question, 3 to 6 months from now I believe we could easily see it trading in the 75 cent area. That price would give a market cap of only $450 million. A company with Three FDA approved drugs not to mention WF10 could command a price higher than that depending on the revenue generated. We will by then likely have a deal to advance WF10 with a large cash payment and royalty deal, Pliaglis, Synera, and Pennsaid 2% either on the market or very close to commercialization. The large cash payment will calm any concerns about funding and we will see increasing Pennsaid sales along with the other products. My guess is we could receive a take over offer before year end of between $1.00 and $1.25 per share. If I had to be nailed down I would guess $1.12.....why would the Zars shareholders and the good Doctor K...accept Nuvo shares for their assets if they felt those shares weren't worth much more than the 5 or 10 cents that they were trading at the time of those separate deals ( May and Dec.)? 

Bullboard Posts